Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Quest PharmaTech Inc
V.QPT
Alternate Symbol(s):
QPTFF
Healthcare
Biotechnology
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company’s lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (TSXV:QPT)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
Next
(99)
•••
G1945V
X
Comment by
G1945V
on Nov 23, 2025 4:46pm
RE:RE:RE:RE:If the only reason oregovomab failed futility analysis....
To Recap: The global Phase 3 clinical trial of oregovomab (FLORA-5) for newly diagnosed advanced ovarian cancer patients was halted in January 2024. The independent Data Safety
...more
(99)
•••
G1945V
X
Comment by
G1945V
on Nov 23, 2025 7:02am
RE:RE:RE:If the only reason oregovomab failed futility analysis....
This is my understanding : Both the Phase 2 and Phase 3 trials of oregovomab compared the combination of carboplatin, paclitaxel, and oregovomab (CPO) to carboplatin and paclitaxel (CP) alone. The
...more
(1)
•••
TrickyGame
X
Comment by
TrickyGame
on Nov 22, 2025 6:14pm
RE:RE:If the only reason oregovomab failed futility analysis....
Gemini: The overall survival (OS) hazard ratio (HR) for oregovomab in the randomized Phase II study (QPT-ORE-002) of front-line chemo-immunotherapy in advanced ovarian cancer was reported as:
...more
(99)
•••
G1945V
X
Comment by
G1945V
on Nov 22, 2025 5:35pm
RE:If the only reason oregovomab failed futility analysis....
The reported overall survival hazard ratio (HR) in Phase 2 was approximately 0.75, indicating a 25% reduction in the risk of death compared to control, though this did not reach statistical
...more
(1)
•••
TrickyGame
X
Post by
TrickyGame
on Nov 20, 2025 12:23pm
If the only reason oregovomab failed futility analysis....
Regardless of who says what on the issue or the susposed blame if it is true that the ONLY reason oregovomab failed the P3 futility analysis was because of the way the trial was structured, does mean
...more
(99)
•••
G1945V
X
Post by
G1945V
on Aug 28, 2025 6:33am
EDMONTON, Alberta, Aug. 27, 2025 (GLOBE NEWSWIRE)
EDMONTON, Alberta, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results of its August 25, 2025 annual general meeting of
...more
(99)
•••
G1945V
X
Comment by
G1945V
on Aug 06, 2025 11:30am
RE:RE:Noise stemming from the company’s CEO
This smells like a power grab by OQP BioM Shareholder Alliance. G1945V
(1)
•••
TrickyGame
X
Comment by
TrickyGame
on Jul 01, 2025 2:45pm
RE:Noise stemming from the company’s CEO
Those are some hefty claims against the CEO of QPT made by OQPBIOM. Claiming he was the cause of oregovomab's failed phase 3 trial. Get
...more
(99)
•••
G1945V
X
Comment by
G1945V
on Jun 27, 2025 10:03am
RE:Noise stemming from the company’s CEO
By what authority does Dr. Madiyalakan, CEO, have the right to make a takeover bid for the biotech firm OQP BioM? G1945V
(0)
•••
DrGreedwell
X
Post by
DrGreedwell
on Jun 26, 2025 10:31am
Noise stemming from the company’s CEO
Dr. Madiyalakan, CEO of Quest PharmaTech, was one of the original developers of Oregovomab and bears significant responsibility for the drug’s clinical trial failure last year. Furthermore, his lack
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 10, 2025 7:15pm
New Press Release - Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech
EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced today that Quest was...
read article.
(1)
•••
TrickyGame
X
Comment by
TrickyGame
on Jun 10, 2025 12:05pm
RE:RE:Oregovomab Phase 3 still going appearently
Its the korean website of OQPBIOM. www.oqpbiom . com just translate the site to English and click on the first link under 'announcements and promtions'
(99)
•••
G1945V
X
Comment by
G1945V
on Jun 10, 2025 6:57am
RE:Oregovomab Phase 3 still going appearently
TG, can you please post the reference from which you obtained this information? G1945V
(1)
•••
TrickyGame
X
Comment by
TrickyGame
on Jun 09, 2025 1:12pm
RE:RE:Quest converted its OQP Bio bonds into shares of OQPBIOM
As an investor in QPT, you are essentially making a bet that one of the 8 trials OQPBioM has ongoing ranging from pre clinical to Phase 3 at least 1 of them becomes a blockbuster treatment and OQPBioM
...more
(1)
•••
TrickyGame
X
Post by
TrickyGame
on Jun 09, 2025 10:59am
Oregovomab Phase 3 still going appearently
OQPBIOM just gained management control of ADBIOTECH, an immune antibody development company and beecame its largest shareholder. This was posted today and included ":OQM is
...more
Prev
1
2
3
4
5
6
7
8
9
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Eshbal quickly expanding commercial and consumer footprint for gluten-free and health food brands
Podcasts